Basic infors:
English name: AZD 3759
English Synonyms: AZD 3759; AZD3759; AZD-3759; (2R) -2,4-Dimethyl- 1-piperazinecarboxylic acid 4 - [(3-chloro-2- fluorophenyl) amino] HY-18750; azd3579;
CAS number: 1626387-80-1
Molecular formula: C22H23ClFN5O3
Molecular weight: 459.91
AZD3759 description
AZD3759 is a potent, orally active, CNS-permeable EGFR inhibitor with IC50 of 0.3 nM, 0.2 nM and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del, . AZD3759 inhibits EGFR phosphorylation with IC50 of 7.2 nM. AZD3759 showed an inhibitory effect on the proliferation of PC-9 and H3255 cells derived from the pEGFR pathway and the EGFR mutant with IC50 of 7.7 nM and 7 nM, respectively, with no activity on the proliferation of H838 cells.
Phase 1 clinical trials of AZD3759 showed very good control activity of intracranial lesions, and the dose of this drug is recommended to be 200 mg or 300 mg twice daily. AZD3759 has no better control of extracranial lesions than the other EGFR-targeted agents, but shows greater control over intracranial lesions.
Patients with meningeal metastases from this clinical trial benefit from the treatment of AZD3759, and the 300 mg dose appears to achieve greater control.
Application
1.Non-small cell lung cancer is one of the major diseases that threaten human health. Even more serious is up to 50% of cancer patients with central nervous system metastasis in their lifetime, metastatic lung cancer is currently no cure. Recently, AstraZeneca's Chinese team led by Dr. Zhang Xiaolin successfully developed a new drug, AZD3759, to treat central nervous system metastases of lung cancer. Their early R & D results have been published in "Journal of Medicinal Chemistry".
2.In order to solve the challenging problem of blood-brain barrier, the author comprehensively optimizes structural parameters such as molecular size, polarity, rigidity and the like, and adjusts various biophysical and chemical properties such as basicity, water solubility, permeability and stability To the best condition to cross the blood-brain barrier. The fully optimized design has successfully brought AZD3759 to the same effective concentrations in different settings of the blood and central nervous system. In addition, the authors also published a preclinical in vitro and in vivo assessment of a subset of candidate compounds. Clinical studies of AZD3759 are underway.
 Our advantages:
 1.Our company is a professional raw powder factory in China for over 10  years, all powders are factory directly supplying.
 2. Our products have exported to Germany, Norway, Poland, Finland, Spain, UK, France,  Russia, USA, Australia, Japan, Korea     and many other countries, over 100kgs each month.
Â
 3.Professional team special for package and shipment and staring on tracking code 24hours for  customs pass guaranteed.      100% pass to UK, Norway, Poland, Spain, USA, Canada, Brazil;  98% pass to Germany, Russia, Australia, New ZealandÂ
  Most of powders are in stock, Chargeable samples are available, Could be shipped out within  24hours.
  High quality, good price, fast and safety delivery. Shipment by DHL, TNT, FEDEX, HKEMS,  UPS, etc.Â
Packing?
1. food bag packing
2. according to your suggestion
2. change the name to ship  your parcel
Â
99% Purity AZD3759 Powder for Cancer treatment 1626387-80-1
Basic infors:
English name: AZD 3759
English Synonyms: AZD 3759; AZD3759; AZD-3759; (2R) -2,4-Dimethyl- 1-piperazinecarboxylic acid 4 - [(3-chloro-2- fluorophenyl) amino] HY-18750; azd3579;
CAS number: 1626387-80-1
Molecular formula: C22H23ClFN5O3
Molecular weight: 459.91
AZD3759 description
AZD3759 is a potent, orally active, CNS-permeable EGFR inhibitor with IC50 of 0.3 nM, 0.2 nM and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del, . AZD3759 inhibits EGFR phosphorylation with IC50 of 7.2 nM. AZD3759 showed an inhibitory effect on the proliferation of PC-9 and H3255 cells derived from the pEGFR pathway and the EGFR mutant with IC50 of 7.7 nM and 7 nM, respectively, with no activity on the proliferation of H838 cells.
Phase 1 clinical trials of AZD3759 showed very good control activity of intracranial lesions, and the dose of this drug is recommended to be 200 mg or 300 mg twice daily. AZD3759 has no better control of extracranial lesions than the other EGFR-targeted agents, but shows greater control over intracranial lesions.
Patients with meningeal metastases from this clinical trial benefit from the treatment of AZD3759, and the 300 mg dose appears to achieve greater control.
Application
1.Non-small cell lung cancer is one of the major diseases that threaten human health. Even more serious is up to 50% of cancer patients with central nervous system metastasis in their lifetime, metastatic lung cancer is currently no cure. Recently, AstraZeneca's Chinese team led by Dr. Zhang Xiaolin successfully developed a new drug, AZD3759, to treat central nervous system metastases of lung cancer. Their early R & D results have been published in "Journal of Medicinal Chemistry".
2.In order to solve the challenging problem of blood-brain barrier, the author comprehensively optimizes structural parameters such as molecular size, polarity, rigidity and the like, and adjusts various biophysical and chemical properties such as basicity, water solubility, permeability and stability To the best condition to cross the blood-brain barrier. The fully optimized design has successfully brought AZD3759 to the same effective concentrations in different settings of the blood and central nervous system. In addition, the authors also published a preclinical in vitro and in vivo assessment of a subset of candidate compounds. Clinical studies of AZD3759 are underway.
 Our advantages:
 1.Our company is a professional raw powder factory in China for over 10  years, all powders are factory directly supplying.
 2. Our products have exported to Germany, Norway, Poland, Finland, Spain, UK, France,  Russia, USA, Australia, Japan, Korea     and many other countries, over 100kgs each month.
Â
 3.Professional team special for package and shipment and staring on tracking code 24hours for  customs pass guaranteed.      100% pass to UK, Norway, Poland, Spain, USA, Canada, Brazil;  98% pass to Germany, Russia, Australia, New ZealandÂ
  Most of powders are in stock, Chargeable samples are available, Could be shipped out within  24hours.
  High quality, good price, fast and safety delivery. Shipment by DHL, TNT, FEDEX, HKEMS,  UPS, etc.Â
Packing?
1. food bag packing
2. according to your suggestion
2. change the name to ship  your parcel
Â
99% Purity Azd3759 Powder for Cancer Treatment 1626387-80-1
Model NO.: 1626387-80-1
Appearance: White or off-White Crystalline Powder
Price: Negotiation
Manufacturer: Quanao Chemical
Delivery Time: 4-7 Days
Trademark: Quanao
Transport Package: Foil Bag or Tin. &Well Disguised Package with Fast
Specification: ISO9001, GMP
Origin: Guangzhou, China
HS Code: 3004409061
Model NO.: 1626387-80-1
Appearance: White or off-White Crystalline Powder
Price: Negotiation
Manufacturer: Quanao Chemical
Delivery Time: 4-7 Days
Trademark: Quanao
Transport Package: Foil Bag or Tin. &Well Disguised Package with Fast
Specification: ISO9001, GMP
Origin: Guangzhou, China
HS Code: 3004409061
99% Purity AZD3759 Powder for Cancer treatment 1626387-80-1